| Authors: |
Begley CG; 7 Grieve Parade, Altona, Victoria, Australia., Ashton M; UniQuest Pty Ltd., University of Queensland, Brisbane, Queensland, Australia., Baell J; Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia., Bettess M; Brandon Capital Partners, Melbourne, Victoria, Australia., Brown MP; Cancer Clinical Trials Unit, Royal Adelaide Hospital, Adelaide, South Australia, Australia., Carter B; Bioseer Pty Ltd., Glen Iris, Victoria, Australia., Charman WN; Monash Institute of Pharmaceutical Sciences, Parkville, Victoria, Australia., Davis C; Institute for Glycomics, Griffith University, Gold Coast campus, Queensland, Australia., Fisher S; Novartis Pharmaceuticals Australia Pty Ltd., Macquarie Park, New South Wales, Australia., Frazer I; University of Queensland Diamantina Institute, Woolloongabba, Queensland, Australia., Gautam A; Pfizer, Melbourne, Victoria, Australia., Jennings MP; Institute for Glycomics, Griffith University, Gold Coast campus, Queensland, Australia., Kearney P; Merck Sharp & Dohme, Macquarie Park, New South Wales, Australia., Keeffe E; Institute for Glycomics, Griffith University, Gold Coast campus, Queensland, Australia., Kelly D; Department of Medicine, University of Melbourne, Parkville, Victoria, Australia., Lopez AF; Centre for Cancer Biology, Adelaide, South Australia, Australia., McGuckin M; University of Melbourne, Parkville, Victoria, Australia., Parker MW; Bio21 Molecular Science and Biotechnology Institute, Parkville, Victoria, Australia., Rayner C; Certara, Parkville, Victoria, Australia., Roberts B; Novartis Pharmaceuticals Australia Pty Ltd., Macquarie Park, New South Wales, Australia., Rush JS; Novartis Pharmaceuticals AG, Basel, Switzerland., Sullivan M; Medicines Development for Global Health, Southbank, Victoria, Australia. |
